Clinical Cancer Research Acceptance Rate
Clinical Cancer Research does not publish a strong official acceptance rate. The better submission question is whether the study bridges laboratory cancer science and clinical application at the AACR translational standard.
Senior Researcher, Oncology & Cell Biology
Author context
Specializes in manuscript preparation and peer review strategy for oncology and cell biology, with deep experience evaluating submissions to Nature Medicine, JCO, Cancer Cell, and Cell-family journals.
Journal evaluation
Want the full journal picture?
See scope, selectivity, submission context, and what editors actually want before you decide whether the journal is realistic.
Quick answer: there is no strong official Clinical Cancer Research acceptance-rate number you should treat as exact. The better submission question is whether the study bridges laboratory cancer science and clinical application. With a recent impact factor of ~10–12, CCR is the AACR's flagship translational journal — and the editorial bar is about the bench-to-bedside bridge, not just scientific rigor.
If the paper is purely basic cancer biology without a translational connection, the acceptance-rate discussion is mostly noise. The clinical relevance is the real issue.
What you can say honestly about the acceptance rate
The AACR publishes a journal metrics page, but Clinical Cancer Research does not disclose a stable acceptance-rate figure on its public pages.
Third-party aggregators report varying estimates, but none have been confirmed by the AACR. The journal publishes twice monthly, providing substantial capacity for translational cancer research, but the editorial bar remains high.
What is stable is the editorial posture:
- CCR sits between Cancer Research (basic) and JCO (clinical) in the AACR portfolio
- the journal requires a translational angle: bench findings with clinical implications, or clinical data with mechanistic insight
- targeted therapies, biomarkers, drug resistance, immunotherapy, pharmacogenomics, and diagnostic innovation are core areas
- the AACR's journal selector tool helps authors find the right AACR venue
That translational identity is the real filter. Papers whose primary advance is purely mechanistic belong in Cancer Research; papers whose primary advance is a clinical trial result belong in JCO.
What the journal is really screening for
At triage, the editor is usually asking:
- does this study connect a laboratory finding to a clinical cancer application?
- is there a biomarker, therapeutic target, resistance mechanism, or diagnostic advance?
- would clinical oncologists find this relevant to patient management?
- does the work bridge the gap between basic cancer biology and clinical practice?
Papers that clearly occupy the translational space — with both laboratory depth and clinical relevance — survive triage at much higher rates.
The better decision question
For Clinical Cancer Research, the useful question is:
Does this study bridge the laboratory and the clinic in a way that could influence cancer treatment, diagnosis, or risk stratification?
If yes, the journal is a strong fit. If the paper is purely mechanistic or purely clinical without a translational bridge, the acceptance rate is not the constraint. The translational positioning is.
Where authors usually get this wrong
The common misses are:
- centering strategy around an unofficial percentage instead of checking translational fit
- submitting basic cancer biology without a clinical bridge (belongs in Cancer Research)
- submitting clinical trial results without mechanistic insight (belongs in JCO)
- ignoring the AACR journal selector tool, which routes manuscripts across the portfolio
- underestimating CCR's emphasis on therapeutic and diagnostic innovation
Those are positioning problems before they are rate problems.
What to use instead of a guessed percentage
If you are deciding whether to submit, these pages are more useful than an unofficial rate:
- Clinical Cancer Research cover letter
- Cancer Research acceptance rate (AACR basic science journal)
- Journal of Clinical Oncology acceptance rate (ASCO clinical trials)
Together, they tell you whether the paper occupies the right translational space, and whether a different oncology venue would be a cleaner first submission.
Practical verdict
The honest answer to "what is the Clinical Cancer Research acceptance rate?" is that the AACR does not publish one, and third-party estimates should not be treated as precise.
The useful answer is:
- yes, this is a selective translational cancer journal
- no, a guessed percentage is not the right planning tool
- use translational positioning, clinical relevance, and the bench-to-bedside bridge as the real filter instead
If you want help pressure-testing whether this manuscript occupies the translational space CCR demands, a free Manusights scan is the best next step.
Sources
- 1. Clinical Cancer Research, AACR, AACR Journals.
- 2. AACR Journals Metrics, AACR.
- 3. Select an AACR Journal, AACR.
- 4. Clarivate Journal Citation Reports, 2025 edition.
Reference library
Use the core publishing datasets alongside this guide
This article answers one part of the publishing decision. The reference library covers the recurring questions that usually come next: how selective journals are, how long review takes, and what the submission requirements look like across journals.
Dataset / reference guide
Peer Review Timelines by Journal
Reference-grade journal timeline data that authors, labs, and writing centers can cite when discussing realistic review timing.
Dataset / benchmark
Biomedical Journal Acceptance Rates
A field-organized acceptance-rate guide that works as a neutral benchmark when authors are deciding how selective to target.
Reference table
Journal Submission Specs
A high-utility submission table covering word limits, figure caps, reference limits, and formatting expectations.
Before you upload
Want the full journal picture?
Scope, selectivity, what editors want, common rejection reasons, and submission context, all in one place.
These pages attract evaluation intent more than upload-ready intent.
Anthropic Privacy Partner. Zero-retention manuscript processing.
Where to go next
Supporting reads
Conversion step
Want the full journal picture?
These pages attract evaluation intent more than upload-ready intent.